Evidence map›Paper›PMID 35200609›Full record

ArticleMarine drugs2022

New Secondary Metabolites from the Marine-Derived Fungus

Kai Zhang, Xinwan Zhang, Rui Lin, Haijin Yang, Fuhang Song, Xiuli Xu, Long Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Talaroterpenoids A-F: Six NewMarine drugs · 2024
    Article
  2. Secondary Metabolites from Marine-Derived FungusJournal of fungi (Basel, Switzerland) · 2024
    Article
  3. Article
  4. Article
  5. Anti-Candidal Marine Natural Products: A Review.Journal of fungi (Basel, Switzerland) · 2023
    Review
  6. Review
  7. MarineMarine drugs · 2023
    Review
  8. Marine Compounds with Anti-Journal of fungi (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kai ZhangSchool of Light Industry, Beijing Technology and Business University, Beijing 100048, China.
Xinwan ZhangSchool of Ocean Sciences, China University of Geosciences, Beijing 100083, China.
Rui LinSchool of Ocean Sciences, China University of Geosciences, Beijing 100083, China.
Haijin YangSchool of Ocean Sciences, China University of Geosciences, Beijing 100083, China.
Fuhang SongSchool of Light Industry, Beijing Technology and Business University, Beijing 100048, China.ORCID 0000-0002-9162-3355
Xiuli XuSchool of Ocean Sciences, China University of Geosciences, Beijing 100083, China.
Long WangKey Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.

Funding

Research Foundation for Advanced Talents of Beijing Technology and Business University 19008021176the National Key R&D Program of China 2018YFC0311000the National Natural Science Foundation of China 81973204
6 · The paper itself

Abstract

Seven new compounds, namely talaromanloid A (

Indexed as

Anti-Infective AgentsCandida albicansChinaEscherichia coliGeologic SedimentsOceans and SeasSecondary MetabolismStaphylococcus aureusTalaromycesAnti-Infective Agentsantibacterialantifungalmarine-derived fungusTalaromyces mangshanicus

Identifiers

PMID35200609
PMCPMC8879399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.